Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS - Get Free Report) in a research report issued on Sunday. The brokerage set a "sell" rating on the biotechnology company's stock.

A number of other brokerages have also issued reports on CLLS. Oppenheimer decreased their target price on shares of Cellectis from $11.00 to $10.00 and set an "outperform" rating on the stock in a research report on Wednesday, June 12th. JMP Securities restated a "market outperform" rating and set a $6.00 target price on shares of Cellectis in a research report on Friday, May 31st.

Cellectis Price Performance

Shares of CLLS traded up $0.05 during mid-day trading on Friday, reaching $2.37. 72,965 shares of the company's stock were exchanged, compared to its average volume of 51,360. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.69. The company has a 50-day simple moving average of $2.07 and a two-hundred day simple moving average of $2.49. Cellectis has a 52-week low of $0.96 and a 52-week high of $3.77. The company has a market cap of $131.73 million, a price-to-earnings ratio of -1.84 and a beta of 3.10.

Cellectis (NASDAQ:CLLS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 28th. The biotechnology company reported ($0.15) earnings per share for the quarter. Cellectis had a negative return on equity of 67.41% and a negative net margin of 529.81%. The business had revenue of $6.50 million for the quarter. On average, sell-side analysts predict that Cellectis will post -0.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellectis

Hedge funds have recently made changes to their positions in the stock. Baillie Gifford & Co. boosted its holdings in shares of Cellectis by 1.3% in the 1st quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company's stock valued at $2,192,000 after purchasing an additional 10,605 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Cellectis by 6.2% during the 1st quarter. Principal Financial Group Inc. now owns 424,533 shares of the biotechnology company's stock valued at $1,125,000 after acquiring an additional 24,906 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Cellectis during the 2nd quarter valued at $29,000. Finally, Long Focus Capital Management LLC lifted its holdings in shares of Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company's stock valued at $8,634,000 after acquiring an additional 130,000 shares in the last quarter. Institutional investors and hedge funds own 63.90% of the company's stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.